Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed's flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed's delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company's products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:ORMP
- CUSIP: N/A
- Web: www.oramed.com
Capitalization:- Market Cap: $127.88 million
- Outstanding Shares: 13,320,000
Average Prices:- 50 Day Moving Avg: $8.43
- 200 Day Moving Avg: $7.66
- 52 Week Range: $5.70 - $10.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.28
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $2.19 million
- Price / Sales: 58.45
- Book Value: $1.49 per share
- Price / Book: 6.45
Profitability:- EBIDTA: ($11,450,000.00)
- Return on Equity: -54.96%
- Return on Assets: -29.63%
Debt:- Current Ratio: 5.24%
- Quick Ratio: 5.24%
Misc:- Average Volume: 51,850 shs.
- Beta: 0.37
- Short Ratio: 5.93
Frequently Asked Questions for Oramed Pharmaceuticals (NASDAQ:ORMP)
What is Oramed Pharmaceuticals' stock symbol?
Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."
When will Oramed Pharmaceuticals make its next earnings announcement?
Where is Oramed Pharmaceuticals' stock going? Where will Oramed Pharmaceuticals' stock price be in 2017?
1 analysts have issued twelve-month target prices for Oramed Pharmaceuticals' stock. Their predictions range from $25.00 to $25.00. On average, they expect Oramed Pharmaceuticals' share price to reach $25.00 in the next year. View Analyst Ratings for Oramed Pharmaceuticals.
Who are some of Oramed Pharmaceuticals' key competitors?
Some companies that are related to Oramed Pharmaceuticals include Nabriva Therapeutics AG (NBRV), Organovo Holdings (ONVO), Horizon Discovery Group PLC (HZD), Organovo Holdings (ONVO), Chromadex Corp (CDXC), Advaxis (ADXS), Merrimack Pharmaceuticals (MACK), Compugen (CGEN), OncoMed Pharmaceuticals (OMED), Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST), Genocea Biosciences (GNCA), CTI BioPharma Corp. (CTIC), Pluristem Therapeutics (PSTI), Regulus Therapeutics (RGLS), Novelion Therapeutics (NVLN), GTx (GTXI) and Silence Therapeutics plc (SLN).
Who are Oramed Pharmaceuticals' key executives?
Oramed Pharmaceuticals' management team includes the folowing people:
- Harold Jacob M.D., Chairman of the Board
- Nadav Kidron, President, Chief Executive Officer, Director
- Hilla Eisenberg, Chief Financial Officer, Treasurer, Secretary
- Joshua Hexter, Chief Operating Officer, Vice President - Business Development
- Miriam Kidron Ph.D., Chief Medical and Technology Officer, Director
- Ronald Edward Law, Chief Strategy Officer
- Roy Eldor M.D, Director
- Ele Ferrannini M.D, Director
- Avram Hershko M.D., Ph.D., Director
- Michael Berelowitz M.D.,, Independent Director
Who owns Oramed Pharmaceuticals stock?
Oramed Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include PNC Financial Services Group Inc. (0.16%), Virtu KCG Holdings LLC (0.12%) and Wells Fargo & Company MN (0.11%). Company insiders that own Oramed Pharmaceuticals stock include Michael Berelowitz, Miriam Kidron, Nadav Kidron and Xiaopeng Li. View Institutional Ownership Trends for Oramed Pharmaceuticals.
Who bought Oramed Pharmaceuticals stock? Who is buying Oramed Pharmaceuticals stock?
Oramed Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Virtu KCG Holdings LLC and Wells Fargo & Company MN. Company insiders that have bought Oramed Pharmaceuticals stock in the last two years include Nadav Kidron and Xiaopeng Li. View Insider Buying and Selling for Oramed Pharmaceuticals.
How do I buy Oramed Pharmaceuticals stock?
Shares of Oramed Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oramed Pharmaceuticals' stock price today?
One share of Oramed Pharmaceuticals stock can currently be purchased for approximately $9.61.
MarketBeat Community Rating for Oramed Pharmaceuticals (NASDAQ ORMP)MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Oramed Pharmaceuticals (NASDAQ:ORMP)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Oramed Pharmaceuticals (NASDAQ:ORMP)Current Year EPS Consensus Estimate: $-0.9 EPS
Next Year EPS Consensus Estimate: $-1.53 EPS
Dividend History for Oramed Pharmaceuticals (NASDAQ:ORMP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Oramed Pharmaceuticals (NASDAQ:ORMP)Insider Ownership Percentage: 27.50%
Institutional Ownership Percentage: 1.34%
Insider Trades by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/2/2017 | Xiaopeng Li | Director | Buy | 89,636 | $8.50 | $761,906.00 |  |
| 4/19/2017 | Miriam Kidron | Insider | Sell | 52,814 | $6.33 | $334,312.62 | |
| 5/12/2016 | Nadav Kidron | CEO | Buy | 1,000 | $6.95 | $6,950.00 | |
| 12/30/2015 | Miriam Kidron | CTO | Sell | 50,000 | $8.90 | $445,000.00 | |
| 12/9/2015 | Michael Berelowitz | Director | Sell | 700 | $9.44 | $6,608.00 | |
| 12/8/2015 | Michael Berelowitz | Director | Sell | 1,300 | $8.70 | $11,310.00 | |
| 3/19/2015 | Nadav Kidron | CEO | Buy | 2,600 | $3.88 | $10,088.00 | |
| 9/11/2014 | Miriam Kidron | CTO | Sell | 31,699 | $8.41 | $266,588.59 | |
| 9/10/2014 | Miriam Kidron | CTO | Sell | 23,000 | $8.40 | $193,200.00 | |
| 9/4/2014 | Miriam Kidron | CTO | Sell | 8,301 | $9.41 | $78,112.41 | |
| 6/6/2014 | Regals Capital Management Lp | Major Shareholder | Buy | 2,252 | $4.44 | $9,998.88 | |
| 3/31/2014 | Michael Berelowitz | Director | Sell | 9,434 | $10.50 | $99,057.00 | |
| 3/25/2014 | Regals Capital Management Lp | major shareholder | Buy | 75,000 | $10.62 | $796,500.00 | |
| 2/6/2014 | Regals Capital Management Lp | major shareholder | Buy | 51,292 | $15.61 | $800,668.12 | |
| 7/10/2013 | Regals Capital Management Lp | Major Shareholder | Buy | 6,630 | $7.40 | $49,062.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Oramed Pharmaceuticals (NASDAQ:ORMP)
Latest Headlines for Oramed Pharmaceuticals (NASDAQ:ORMP)
| Source: |
|
| Date | Headline |
|---|
 | Critical Analysis: Portola Pharmaceuticals (PTLA) versus Oramed Pharmaceuticals (ORMP)
www.americanbankingnews.com - September 12 at 2:26 AM |
| Oramed Pharmaceuticals Inc. (ORMP) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - September 6 at 11:02 PM |
 | Oramed Pharma (ORMP) Says FDA Meeting Provides BLA Guidance on ORMD-0801
www.streetinsider.com - September 6 at 7:16 AM |
 | Oramed Announces Successful Meeting with FDA for Oral Insulin
finance.yahoo.com - September 6 at 7:16 AM |
| Oramed (ORMP): Successful Meeting with FDA for Oral Insulin
finance.yahoo.com - September 6 at 7:16 AM |
| Oramed Pharmaceuticals Inc. (ORMP) Expected to Post Quarterly Sales of $610,000.00
www.americanbankingnews.com - September 4 at 7:30 AM |
| Oramed to Present at the Rodman & Renshaw Global Investment Conference
finance.yahoo.com - August 30 at 7:40 AM |
| Oramed Pharmaceuticals Inc. (ORMP) Expected to Announce Quarterly Sales of $610,000.00
www.americanbankingnews.com - August 17 at 9:48 AM |
| Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Director Purchases $761,906.00 in Stock
www.americanbankingnews.com - August 3 at 7:52 PM |
| Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Expected to Post Quarterly Sales of $610,000.00
www.americanbankingnews.com - July 29 at 7:21 AM |
| Analysts Anticipate Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Will Announce Earnings of -$0.28 Per Share
www.americanbankingnews.com - July 27 at 8:10 PM |
| Oramed Pharma (ORMP) CFO Resigns - StreetInsider.com
www.streetinsider.com - July 22 at 7:22 AM |
 | Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs - PR Newswire (press release)
www.prnewswire.com - July 19 at 1:09 AM |
| Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs
finance.yahoo.com - July 19 at 1:09 AM |
| Oramed to Present at BIT'S 5th World Congress of Diabetes on July 13, 2017
finance.yahoo.com - July 13 at 7:42 AM |
 | ORMP To Meet With FDA, Second Time's No Charm For OCUL, Panel Backs PFE
www.rttnews.com - July 12 at 6:42 AM |
| Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program
finance.yahoo.com - July 12 at 6:42 AM |
| Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q3, 2017 By the Numbers : July 10, 2017
finance.yahoo.com - July 11 at 6:25 AM |
| Head to Head Review: Oramed Pharmaceuticals (ORMP) vs. ImmunoGen (IMGN)
www.americanbankingnews.com - July 10 at 10:28 PM |
| Oramed reports 3Q loss
finance.yahoo.com - July 7 at 7:54 AM |
| Oramed Announces Dual-Listing on Tel Aviv Stock Exchange
finance.yahoo.com - July 5 at 9:21 AM |
| Oramed Granted Japanese Patent for Combination Insulin and GLP-1 Analog Capsule
finance.yahoo.com - June 27 at 7:12 PM |
| Short Interest in Oramed Pharmaceuticals Inc. (ORMP) Expands By 1.9%
www.americanbankingnews.com - June 15 at 7:12 AM |
| Oramed Plans Secondary Listing in Tel Aviv Soon, CEO Kidron Says
finance.yahoo.com - June 12 at 6:45 PM |
| Oramed Pharmaceuticals, Inc. (ORMP) Expected to Post Quarterly Sales of $610,000.00
www.americanbankingnews.com - June 9 at 1:31 PM |
| Analysts Anticipate Oramed Pharmaceuticals, Inc. (ORMP) Will Post Earnings of -$0.27 Per Share
www.americanbankingnews.com - June 7 at 2:16 PM |
| Oramed to Present at the American Diabetes Association 77th Scientific Sessions - PR Newswire (press release)
www.prnewswire.com - June 6 at 7:49 PM |
| Oramed to Present at the American Diabetes Association 77th Scientific Sessions
finance.yahoo.com - June 6 at 7:49 PM |
| SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oramed Pharmaceuticals Inc. for - PR Newswire (press release)
www.prnewswire.com - June 5 at 7:40 PM |
| SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oramed Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - June 5 at 7:40 PM |
| Oramed Pharmaceuticals, Inc. (ORMP) PT Set at $25.00 by HC Wainwright
www.americanbankingnews.com - May 23 at 8:43 PM |
| Oramed to Present at Conferences Next Week
finance.yahoo.com - May 19 at 11:50 AM |
| Oramed Pharma (ORMP) Announces Canadian Patent for GLP-1 Analog Capsul - StreetInsider.com
www.streetinsider.com - May 10 at 11:49 AM |
| Oramed Pharma (ORMP) Announces Canadian Patent for GLP-1 Analog Capsul
www.streetinsider.com - May 9 at 11:16 AM |
| Oramed Granted Canadian Patent for GLP-1 Analog Capsule
finance.yahoo.com - May 9 at 11:16 AM |
| Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q2, 2017 By the Numbers : May 5, 2017
finance.yahoo.com - May 5 at 7:20 PM |
| Oramed (ORMP) to Conduct Human Study for New Oral Leptin Capsule
finance.yahoo.com - May 2 at 4:51 PM |
| Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule - PR Newswire (press release)
www.prnewswire.com - May 2 at 11:10 AM |
| Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule
finance.yahoo.com - May 2 at 11:10 AM |
| Oramed Gaining Strength in Oral Diabetes Market
finance.yahoo.com - May 1 at 5:58 PM |
| Oramed Pharma (ORMP) Says EPO Granted Patent for Combination Oral Insulin and GLP-1 Analog Capsule - StreetInsider.com
www.streetinsider.com - April 21 at 12:12 AM |
| Oramed Granted European Patent for Combination Oral Insulin and GLP-1 Analog Capsule - Yahoo Finance
finance.yahoo.com - April 20 at 9:04 AM |
| Oramed Granted European Patent for Combination Oral Insulin and GLP-1 Analog Capsule
finance.yahoo.com - April 20 at 9:04 AM |
| Insider Selling: Oramed Pharmaceuticals, Inc. (ORMP) Insider Sells 52,814 Shares of Stock
www.americanbankingnews.com - April 19 at 7:53 PM |
 | Oramed reports 2Q loss
marketbeat.com - April 6 at 5:04 AM |
| Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017
finance.yahoo.com - March 22 at 9:02 AM |
| Oramed Pharma (ORMP) Appoints Dr. Ronald Law as CSO - StreetInsider.com
www.streetinsider.com - March 21 at 11:12 AM |
| Oramed Appoints Dr. Ronald Law as Chief Strategy Officer
finance.yahoo.com - March 21 at 11:12 AM |
| ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 21 at 11:12 AM |
 | Here's Where Oramed Fits Into The Diabetes Space
seekingalpha.com - February 17 at 4:45 PM |
Oramed Pharmaceuticals (ORMP) Chart for Wednesday, September, 20, 2017
